Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer

NCT00958971 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: TKI258

Sponsor

Novartis Pharmaceuticals